rounding the initial diagnosis and treatment of the physical illness and the psychosocial concerns that surround the disease. Compliance with the federal guidelines related to anti-discrimination laws and benefits are discussed, and the vital role of the occupational health nurse is highlighted.
REVIEW OF THE DISEASE
Acquired immunodeficiency syndrome (AIDS) is caused by a human immunodeficiency virus (HIV), a retrovirus dependent on a DNA host for replication. The lymphocytes were once thought to be the major infected cell within the body, but any cell can be infected. Once a person becomes infected with the virus, the code for multiplication ofthe virus has become a permanent part of the host's DNA.
One can acquire HIV by having unprotected sex with some-one who is infected with HIV or by sharing drug needles and syringes with an infected person. Newborns born to HIV infected mothers may be infected during pregnancy or delivery. In the past, blood products, i.e., transfusions or hemophiliac factors, have been a source of infection. However, since April 1985 the blood supply has been screened for HIV Organ transplants also can be a source of infection.
In the U.S. there have been over 250,000 reported AIDS cases. Estimates for HIV infection worldwide are 3 to 5 million. Within time, the transmission of HIV should become equal between heterosexuals and homosexuals. Among women, the incidence of contracting HIV is growing at a 40% higher rate than that of males (Department of Health & Rehabilitative Services, 1993) .
DIAGNOSTIC TESTING
Screening for HIV should be performed by a health care professional who obtains a written consent and discusses the purpose of the test. Results should be interpreted by the occupational health nurse or other health care professional and should be shared only with the tested individual. Confidentiality cannot be assured over the telephone, and the reaction of the employee cannot be appropriately monitored. Risk behav-ior reduction should be discussed regardless of the test result. If an employee tests negative, follow up testing is advised in 6 months for confirmation.
After the employee is diagnosed with HIV, many questions will be asked about drug intervention. T cells are the marker for measuring the immune status of persons who are HIV positive; measurements should be repeated periodically to monitor illness. The most important value to follow is the absolute CD4 helper T cell. Those employees who have healthier immune systems, i.e., absolute CD4 counts >500, are usually informed that no drug therapy is indicated at the present time, but T cell studies should be performed approximately every 3 months.
PSYCHOSOCIAL CONSIDERATIONS
After the initial diagnosis, it is very important that the employee have the opportunity to discuss the implications of testing positive and how this might impact the employee's daily living. It is preferable that discussions of this nature be with a counselor or HIV support group. Some employees will consider testing positive a death sentence and inappropriately start preparing for death in radical terms. Some individuals may respond by spending savings on vacations and automobiles, assuming that time is very limited. Other individuals may break relationships and retreat from society. Those in a relationship often feel a sense of betrayal.
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ART I C L E Religious issues may become intense, and guilt over risk behaviors may be present (Volberding, 1992) . Post-diagnosis is a critical time when personal friends and family mayor may not know the employee's difficulties and may also unconsciously contribute to the stress in the employee's life. Professional counseling should be considered for every newly diagnosed employee as part of the ongoing team approach for the employee's care. The occupational health nurse should be a member of the team, helping the employee deal with workplace concerns. The employee's benefits and insurance policies should be explained regarding the continued care of the employee during healthy periods, as well as after illnesses occur (Volberding, 1992) .
PROGRESSION OF THE DISEASE
An acute syndrome with rash or fever occurs immediately after exposure or up to 52 weeks postexposure. This syndrome represents a viremia lasting from 1 to 4 weeks, then usually resolving to a latent period in which the virus is less active. The latency period can be documented with laboratory tests. During this latency period, the employee may remain asymptomatic for 2 to 15 years. It has been suggested, however, that lymphoid involvement of the virus may be very active during the latency period, and treatment may be important despite high T cell numbers (Levy, 1993) .
Two of the classic symptoms include weight loss and fatigue. Fatigue is perhaps the most difficult symptom to describe, since depression and generalized anxiety can be present even without organic disease. Since HIV is a viral syndrome, many complaints such as fever, joint pain, and muscle aches are very similar to an episode of the flu. Unfortunately, such complaints can be sustained throughout the symptomatic stages of the disease. It is common practice to place these individuals on nonsteroidal anti-inflammatory drugs for arthralgias and myalgias. Some of the first signs of HIV infection in the employee may be a change in cognitive skills (thinking, reasoning, and problem solving). Coworkers may notice decreased concentration by the employee. This can represent encephalopathy that can occur even very early in the disease process. HIV can infect the neurons and cause alterations in the mentation of individuals who otherwise may not have any of the typical opportunistic infections. Starting or changing antiviral therapy can actually improve the employee's performance. The individual may be able to continue working for years without succumbing to the encephalopathy. On the other hand, individuals may continue to deteriorate despite therapy.
The nurse's evaluation and report to the primary care provider can be invaluable in the drug management for this type of employee (Glaxo, 1991) . Neuropsychological testing may be ordered so that motor and men-CE ART I C L E - tal skills can be objectively evaluated to assist in monitoring the employee's condition. Currently, the International Classification of Diseases (lCD-9) is used to categorize the stage of disease for insurance and disability purposes.
ICD-9 Classifications
044.91. HIV positive individuals, usually asymptomatic except for possible lymphadenopathy.
043.9 2. AIDS related complex-defined by a symptomatic group having low grade fevers , thrush, idiopathic thrombocytopenic purpura (ITP), oral hairy leukoplakia, recurrent infections, weight loss , or some other progressive symptoms.
042.9 3. AIDS-defined as having an opportunistic infection such as Pneumocystis pneumonia, Wasting syndrome, Candida esophagitis, HIV dementia, cytomegalic disease, Cryptococcal meningitis, Mycobacterium avium, or an opportunistic cancer such as Kaposi's sarcoma or lymphoma. MAY 1994, VOL. 42, NO.5 In 1993, the Centers for Disease Control and Prevention reclassified HIV disease into newer categories relating the clinical condition of the employee to the CD4 counts (CDC, 1992 ) . Table 1 summarizes these categories.
CURRENT DRUG TREATMENT REGIMES
Despite the differing views about the drug zidovudine (AZT), it is still considered to be the primary initial drug of choice. This may change as newer drugs become more available. AZT dosage requirements have been reduced since its initial use, allowing most individuals to tolerate the drug at higher T cell levels . At present, AZT treatment is initiated after the CD4 level drops consistently below 500 , as described in Table 3 . The drug is continued until side effects are not tolerated or the CD4 count decline continues despite therapy. Some side effects of AZT include headache, nausea, and, more severely, anemia which may some-times require transfusion. Other drugs, such as erythropoietin, have been used with AZT to maintain adequate hemoglobin (PDR , 1993 ) .
Other side effects of AZT can be muscle aches and pains and muscle wasting (PDR , 1993) . Certainly, after an employee has been on AZT for some time, the incidence of these complaints may increase. In addition, the creatinine phosphokinase lab values may reflect changes in the muscle mass. Additional antiviral and prophylactic agents are summarized in Table 2 . Dideoxycytidine (DDC ) was approved by the FDA in 1992 for combination therapy with AZT. DDC seems to enhance the antiviral effects of AZT, possibly by reducing viral resistance. The side effects of DDC can be very significant, especially at the lower T cell levels . For example, marked neuropathy of the extremities can remain even after the drug is discontinued (Annals of Internal Medicine, 1992) .
Other combinations being tested that have not been ap- proved by the FDA include AZT and didanosine (DDD. DDI alone appears to be very effective as an antiviral agent, especially after the individual has first been on an AZT regimen. Again, viral resistance can occur.
DDI has its own set of side effects. Pancreatitis has been noted in about 10% of individuals treated with DDI. Therefore, it should be avoided in anyone who has had pancreatitis or is unwilling to avoid alcohol while taking the drug. Because it is difficult to absorb, DDI cannot be given with food. It is supplied in both tablet and
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ART I C L E powder form with a significant amount of buffer. Initial therapy with DDI can result in temporary diarrhea which usually resolves in 2 to 3 weeks. For some individuals, diarrhea secondary to DDI use is intolerable and cannot be controlled with the usual prescription drugs. Viral load is an indicator of the level of viral activity in an individual's bloodstream. The concomitant use of AZT and DDI appears to lower the resistance capability of the virus and thus lower viral load (Skidmore-Roth, 1993) . The most common side effects of the major antiretrovi-ral agents are listed in Table 3 .
Triple combination studies are certainly the most hopeful, although studies in humans have not yet been completed. Combinations such as AZT, DDI, and nevirapine hold some promise, but they are not without side effects. The triple drug combination theory involves using drugs that act at different sites, which may lower the total viral load and also reduce the resistance factors. These combinations can then be placed together much like chemotherapy for individuals with cancer.
For employees who cannot tolerate AZT or DDI, other research drugs such as stavudine (d4T) are available. Stavudine is very similar to DDI and AZT, and it has demonstrated some consistent improvement in CD4 counts in preliminary studies involving the higher T cell groups. The drug appears to be well tolerated by persons with the lower T cell group counts. Pancreatitis is a rare, but possible, complication. Unfortunately, neuropathy of the extremities can occur, but lowering the dosage of the d4T has enabled a number ofindividuals to tolerate the drug.
Even though the effectiveness of the current antiviral agents has been questioned, the greatest strides in therapy have been in prophylaxis of some of the opportunistic infections. The overall incidence of Pneumocystis pneumonia (PCP) and toxoplasmosis has been reduced by the use of trimethoprimsulfamethoxazole (TMP-SMX). One double strength tablet each day is given when an individ-CE ART I C L E 
AIDSIHIV Information Resources
American Foundation for AIDS Research (AmFAR) AIDS Clinical Trial Information Service Project Inform Hotline ual's CD4 cells have dropped below 250 or CD4% less than 20%.
Many individuals develop allergic reactions to sulfa compounds. Therefore, pentamidine aerosol, 300 mg once a month, may be used as pulmonary prophylaxis for PCP (PDR, 1993) . The systemic PCP protection and toxoplasmosis prophylaxis from TMP-SMX is the preferred therapy. Thus, some health care providers have instituted desensitization techniques to use TMP-SMX. A third alternative for. PCP prophylaxis is dapsone, 100 mg a day, which also has some allergic potential (PD R, 1993 ) .
In the past, Mycobacterium avium complex (MAC) had not been considered a serious opportunistic infection when compared to other infections such as PCP. However, there was a dramatic increase in incidence of MAC in individuals with CD4 cells less than 100; MAC has a significant impact on the person with AIDS.
The MAC organism, which resembles the Mycobacterium tuberculosis, can present with the same symptoms-fever, night sweats, and weight loss. Often, an examination of the bone marrow is necessary to diagnose an infection. Although clarithromycin has been widely used as a prophylactic agent, the only FDA approved prophylactic regimen is rifabutin, 300 mg a day, for an individual whose CD4 cells are less than 100. Note that the treatment for MAC is different than prophylaxis and should involve multiple agents, MAY 1994, VOL. 42, NO.5 including either clarithromycin or azithromycin.
Vaccine therapy is still used only in the research arena. It is thought that a vaccine, such as the gp160 or the gp120 introduced into the intact immune system, might stimulate antibodies to the virus and therefore may help control the viral activity. For employees who are interested in research protocols, a number of resources are available through the American Federation for AIDS Research (AMFar) and the National Institutes of Health. Table 4 lists national resources for physician referrals, drug information, and research protocols. Both the primary health care provider and the occupational health nurse can be involved in coordinating the referral to a research facility. Participating in a research study may take time away from the workplace. Some understanding ofthese conditions should be discussed with the employee.
IMPACT ON THE WORKPLACE
Each state may have specific legislation to protect workers with HIV. However, the Americans With Disabilities Act (ADA) significantly affects both federal 1-800-36-AmFAR 1-800-874-2572 1-800-822-7422
and private em ployers. In regard to the Act, no employer can discriminate against a person who is HIV positive or has AIDS. Such discrimination applies to hiring, firing, and potential promotions. An employer cannot discriminate in hiring a person who is HIV positive or has AIDS even if the health insurance cost s might rise or the person may become too sick to work in the future. If an HIV test is mandatory, the employer must prove that the test is necessary for the particular job under consideration (ADA, 1990) . Section 504 of the Federal Rehabilitation Act has designated AIDS as a disability and also protects persons with AIDS from discrimination in federally funded facilities. According to the Act , if hospital social workers and discharge planners have difficulty admitting clients into nursing homes with the excuse that "we are not prepared to take AIDS patients" for whatever re ason , the clients are considered victims of discrimination. Letters of complaints regarding specific cases can be sent to the U.S. Department of Health and Human Services, Office of Civil Rights or the local Department of Health & Rehabilitative Services office. The case is then investigated, and if the nursing home or agency is found to have been discriminating, federal funding such as Medicare and Medicaid can be lost.
It is very important for the occupational health nurse to comply with federal mandates to protect the employee's rights. Increasing the team support concept (primary caregiver, occupational health nurse/employer, support group) will allow the employee the greatest length and quality of work productivity. For example, the team may work with an employee experiencing increasing fatigue to establish a more flexible work schedule to maximize individual performance.
Coordination between the primary caregiver and the occupational health nurse will be extremely helpful for establishing alternate duty work and, eventually, time for disability and leave from work. According to the CDC (1992), persons who have less than 200 CD4 absolute cells are classified as having AIDS and therefore could potentially qualify for disability based on progression of illness. Not all insurance companies allow disability on CD4 counts alone. It is necessary to document the se-
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When an employee can no longer perform the essential functions ofthe job and reasonable accommodations by the employer still do not allow the employee to perform the job adequately, then consultation between the employee, occupational health nurse, and the primary caregiver will be necessary to initiate a medical leave or total disability. The occupational health nurse is a vital resource for the employee in relation to the company's insurance and disability benefits, as well as government and private resources.
SUMMARY
The occupational health nurse is the primary workplace educator in the HIV pandemic. The policies and methods used to manage the employee with HIV must protect the confidentiality of the employee without discrimination. The occupational health nurse has a unique responsibility to monitor the disease progression and respond with appropriate recommendations for psychological support, AIDS resources, employee medical leave, and disability benefits. In addi-tion, the occupational health nurse plays a pivotal role with the primary caregiver in clinical management of the employee at the worksite.
